FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
October 26, 2015
GEMS™ Home Rx will be released to address a universal need for cost effective arrhythmia monitoring
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) ") a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, today confirmed the scheduled November release of "GEMS™ Home Rx" which will enable low cost ECG and arrhythmia monitoring for physicians, health professional and ECG service providers.
GEMS™ Home Rx is the newest software release from CardioComm Solutions and combines technologies from the Company's HeartCheck™ ECG devices cleared for consumer and prescription use and their GEMS™ based medical/hospital software. GEMS™ stands for global electrocardiogram ("ECG") management solution (GEMS™)
The expected cost for an annual license of GEMS™ Home Rx will be $500 USD per year. The software will permit an unlimited number of ECGs to be imported and interpreted and will retain the option to allow for ECGs to be uploaded to the Company's SMART Monitoring ECG service if and when it is needed. Both the HeartCheck™ ECG PEN and the HeartCheck™ ECG Monitor will be supported by GEMS™ Home Rx.
GEMS™ Home Rx is a Windows PC based software program that can allow for the collection of ECG recordings from HeartCheck™ ECG devices for viewing, reviewing, reporting and interpretation by qualified health care professionals and physicians. GEMS™ Home Rx is an ultra-lite prescription version of the Company's FDA, Health Canada and European Union compliant GEMS™ WIN software which is used by physicians, hospitals and medical call centers for ambulatory, trans-telephonic, wireless event and mobile cardiac telemetry ECG/arrhythmia monitoring of patients outside the hospital environment. GEMS™ Home, a consumer based, non-ECG analyzing version of GEMS™, was first released when the Company launched the HeartCheck™ ECG PEN. The HeartCheck™ ECG PEN is a personal, single ECG lead, hand-held, Class II medical device cleared for consumer over-the-counter ("OTC") use in Canada and the USA.
What changed with GEMS™ Home Rx vs GEMS™ Home? The Company confirms that there is a market segment that was unable to access CardioComm Solutions' SMART Monitoring ECG service due to a lack of reliable access to the internet, an inability to afford participation in a per ECG software-as-a-service model and a requirement to be able to immediately and easily record and interpret ECGS such as is needed in mass community, inner city or rural health screening undertakings. In response to this, CardioComm Solutions incorporated access to their proprietary ECG viewer, known as GUAVA, so that individual ECGs can now be called up and read on a local PC through GEMS™ Home Rx. The GUAVA environment is the same ECG viewing software system that is used within the company's GEMS™ WIN medical software installations globally.
GEMS™ Home Rx is completing testing and the Company has confirmed that they already have interest from physicians to order HeartCheck™ devices and license the use of the software in different countries. The intent of the release is to provide an easy, cost effective and medically credentialed ECG management solution to large and small medical practices regardless of their access to the internet or cellular coverage. Specific markets will be satellite medical practices as well as underserviced and developing regions where outreach services and community screening programs are needed.
The Company confirms that it will continue to release new product offerings to meet the growing need for more universal and standardized access to ECG testing and to enable new devices to expand the way in which ECG testing can be performed. CardioComm Solutions views the entry of ECG monitoring into the wellness, health and wearable-tech markets as likely. Accordingly, the Company has recognized the importance of reducing the barrier(s) of entry for the expanded use of their ECG monitoring technologies by providing more affordable, easy to use, and yet appropriately regulated, medical software and device solutions.
To learn more about CardioComm Solutions' consumer HeartCheck™ ECG products and their hospital-based ambulatory cardiac arrhythmia technologies GEMS™ WIN, please see the Company's websites at www.theheartcheck.com and www.cardiocommsolutions.com.
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Ontario, Canada.
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.